Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479804 | 1.00 | BACE1 (0.51) | BACE1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL479806 | 1.00 | BACE1 (0.51) | BACE1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL481167 | 0.93 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL481166 | 0.93 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL3159875 | 0.92 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL2569219 | 0.92 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL2572324 | 0.92 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL2572320 | 0.92 | RXFP1 (0.51) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL6771491 | 0.91 | RXFP1 (0.50) | MAPTMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL20807625 | 0.91 | RXFP1 (0.52) | BACE1MAPTMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-9844572-B2 | Promotion of neuronal integration in neural stem cell grafts | LIFE & BRAIN GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| EP-2411034-B1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2411034-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | Life & Brain GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108665-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093832-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | DCX, NGF, BDNF | BACE1 576/4885MAPT 960/4885MEN1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.